Dornase alfa (brand name Pulmozyme) is a synthetic protein that breaks down excess DNA in the pulmonary secretions of people with cystic fibrosis. It improves lung function in CF by thinning thick mucus secretions, allowing the air to flow better, preventing bacteria from causing infections.1

Dornase alfa was approved for use by the FDA in 1993 after a Phase 3 study demonstrated improvement in lung function and reduction in pulmonary exacerbations.2 The solution is inhaled and usually taken once or twice a day.3 It should only be used with a recommended nebulizer after learning the proper technique. Dornase alfa comes as a single-use ampule that should be stored under refrigeration and away from strong light. Then an approved nebulizer, with its components (tubing and mouthpiece) are essential for the correct treatment to be done.

Dornase alfa will treat CF but won’t cure it, so it should be used even if there are no symptoms.

Some of the side effects people may experience are voice changes, sore throat, hoarseness, eye irritation, and rash.1

Dornase alfa is safe and effective in children over 5 years old. Nevertheless, for younger children, its use should be considered when there may be a potential benefit in lung function or who may be at risk of respiratory tract infection. The safety of daily inhalation of dornase alfa has been studied in 98 children (65 of them aged 3 months to <5 years and 33 aged 5 to <10 years). The side effects observed were similar to those seen in older patients.

There are no generics available for dornase alfa.

Cystic Fibrosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.




Hypertonic Saline Prolongs Mucus Clearance in Adult CF Patients, Study Finds

A single dose of inhaled hypertonic saline (HS) solution increases mucus clearance for at least four hours in adults with cystic fibrosis (CF), concludes researchers at the University of North Carolina and John Hopkins University. Their study, “Hypertonic saline has a prolonged effect on mucociliary clearance in adults with cystic fibrosis,” appeared in the Journal of Cystic Fibrosis. It […]

Spyryx to Present Two Studies on SPX-101’s Ability to Treat Cystic Fibrosis by Clearing Airway Mucus

Spyryx Biosciences will present two studies in Washington this week on SPX-101‘s ability to treat cystic fibrosis by clearing mucus from airways. One of the preclinical-trial studies it will discuss at the American Thoracic Society‘s annual convention showed that SPX-101 improved survival in several models of CF-like lung diseases. The event runs from May 19-24. SPX-101 mimics a […]

Mucociliary Clearance, Difficult in CF, Might Be Possible by Blocking Mucus Absorption

Blocking mucus absorption in the airways through the use of certain agents can strengthen an innate airway mechanism, called mucociliary clearance (MCC), that is often impaired in lung diseases such as cystic fibrosis (CF). The study, “Marked increases in mucociliary clearance produced by synergistic secretory agonists or inhibition of the epithelial sodium channel,” was published in the journal Scientific Reports. […]

#NACFC2016 – Getting the Upper Hand on Mucus in Cystic Fibrosis

Abnormal mucus clearance in patients with cystic fibrosis (CF) may be improved with specific treatments, but despite intense research on the subject, there are many unanswered questions about how atypical mucus contributes to the disease and how to best improve the problem. Researchers debated the issue in three discussions at a symposium titled “Mucociliary Transport and […]

#NACFC2016 – Results of Spyryx’s Investigational CF Therapy to Be Presented

Results of the safety, stability, and effectiveness of Spyryx Biosciences‘ drug candidate SPX-101 for cystic fibrosis (CF) will be presented at the North American Cystic Fibrosis Conference (NACFC) Thursday through Saturday in Orlando, Florida. SPX-101 mimics the function of the protein SPLUNC1, which plays an important role in controlling airway surface hydration and mucus clearance, a mechanism […]